Table 3 Use of specific second-line anti-TB or antiretroviral medicines and the risk of moderate-to-severe adverse events
Anti-TB medicine | Number (%) treated with the medicine, N = 57 | Univariate risk ratios | 95% confidence interval | p-value |
|---|---|---|---|---|
Amikacin | 21 (36.8%) | 1.5 | 0.8 – 2.6 | 0.18 |
Amoxicillin/Clavulanate | 1 (1.8%) | 0.0 | - | 0.36 |
Capreomycin | 4 (7%) | 1.1 | 0.4 – 3.1 | 0.86 |
Ciprofloxacin | 19 (33.3%) | 1.5 | 0.8 – 2.5 | 0.19 |
Clofazimine | 1 (1.8%) | 0 | - | 0.36 |
Cycloserine | 27 (47.4%) | 0.8 | 0.5 – 1.5 | 0.49 |
Ethambutol | 35 (61.4%) | 1.7 | 0.9 – 3.4 | 0.10 |
Ethionamide | 52 (91.2%) | 0.7 | 0.3 – 1.6 | 0.50 |
Isoniazid | 4 (7%) | 1.1 | 0.4 – 3.1 | 0.86 |
Kanamycin | 30 (52.6%) | 0.8 | 0.4 – 1.4 | 0.37 |
Levofloxacin | 37 (64.9%) | 0.6 | 0.4 – 1.1 | 0.11 |
Para aminosalicylic acid (PAS) | 5 (8.8%) | 1.4 | 0.6 – 2.9 | 0.50 |
Pyrazinamide | 53 (93%) | 0.9 | 0.3 – 2.5 | 0.86 |
Rifampicin | 13 (22.8%) | 0.8 | 0.4 – 1.7 | 0.56 |
Streptomycin | 3 (5.3%) | 0.7 | 0.1 – 3.6 | 0.66 |
Any HAART regimen | 13 (22.8%) | 0.8 | 0.4 – 1.7 | 0.56 |
Zidovudine (AZT) | 5 (8.8%) | 0.4 | 0.1 – 2.5 | 0.23 |
Stavudine (d4T) | 6 (10.5%) | 1.1 | 0.5 – 2.6 | 0.82 |
Efavirenz (EFV) | 10 (17.5%) | 0.9 | 0.4 – 1.9 | 0.70 |
Nevirapine (NVP) | 3 (5.3%) | 0.7 | 0.1 – 3.7 | 0.66 |